Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 19/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | NFKBIA | P25963 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | ABAT | P80404 | 1/20 | 1.00 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.68 |
| ▸ | CHUK | O15111 | 3/20 | 0.54 |
| ▸ | EPHA3 | P29320 | 3/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4193990 | 0.90 | IKBKB (0.82) | IKBKBGAKICAM1DRD2NFKBIA | |
| SCHEMBL4471305 | 0.89 | IKBKB (0.80) | IKBKBGAKICAM1DRD2NFKBIA | |
| SCHEMBL4190854 | 0.89 | IKBKB (0.80) | IKBKBGAKICAM1DRD2NFKBIA | |
| SCHEMBL13711918 | 0.86 | IKBKB (0.75) | IKBKBGAKICAM1DRD2NFKBIA | |
| SCHEMBL4347213 | 0.83 | IKBKB (0.71) | IKBKBGAKICAM1DRD2NFKBIA | |
| SCHEMBL4194829 | 0.83 | IKBKB (0.70) | IKBKBGAKICAM1DRD2NFKBIA | |
| SCHEMBL4474557 | 0.83 | IKBKB (0.70) | IKBKBGAKICAM1DRD2NFKBIA | |
| SCHEMBL4338637 | 0.82 | IKBKB (0.70) | IKBKBGAKICAM1DRD2NFKBIA | |
| SCHEMBL4338625 | 0.82 | IKBKB (0.70) | IKBKBGAKICAM1DRD2NFKBIA | |
| SCHEMBL4196368 | 0.82 | IKBKB (0.69) | IKBKBGAKICAM1DRD2NFKBIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| EP-4460301-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2024-11-13 | — | — | EP | claimed |
| EP-3720493-B1 | COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES | UNIV KOELN (DE) | 2024-07-24 | — | — | EP | claimed |
| WO-2023131576-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | claimed |
| US-20220110953-A1 | METHODS AND COMPOSITIONS FOR TREATING HUMAN PAPILLOMAVIRUS (HPV)-INDUCED CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2022-04-14 | — | — | US | claimed |
| US-7592353-B2 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | claimed |
| US-20070293533-A1 | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-20 | — | — | US | claimed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| EP-4460301-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2024-11-13 | — | — | EP | disclosed |
| US-20240361301-A1 | METHODS AND COMPOSITIONS FOR MODULATING GOBLET CELLS AND FOR MUCO-OBSTRUCTIVE DISEASES | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2024-10-31 | — | — | US | disclosed |
| US-7592353-B2 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592353-B2 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| WO-2007146602-A1 | SUBSTITUTED 3-AMINO-THIENO[2,3-B] PYRIDINE-2-CARBOXAMIDE COMPOUNDS, THEIR PREPARATION AND USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293533-A1 | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293533-A1 | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293533-A1 | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293533-A1 | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES | NFKBIA, CHUK, IKBKB | IKBKB 3/4885GAK 78/4885ICAM1 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.